Go to main content
Back to Back to kd-ventures.com
SV EN

News Published

Don’t miss the annual report for 2025

2025 was filled with progress in clinical development and strategic collaborations across our portfolio companies. During the latter part of the year, we laid the groundwork for the financing round that was completed at the beginning of 2026, with strong interest from external investors and a broadened shareholder base.

Framsida årsredovisning

During 2025, several of our portfolio companies – AnaCardio, Dilafor, BOOST Pharma, SVF Vaccines and Umecrine Cognition – reached important milestones in clinical development, capitalisation and partnerships. Taken together, the progress confirms the strength of KDventures’ strategy and the portfolio’s long-term value creation potential. 

Read the full annual report for 2025 here.

More news

Viktor Drvota Redeye

Viktor Drvota at Redeye

Watch KDventure's CEO Victor Drvota present the company's investment strategy and answer questions.

Publicerad: 5 March, 2026

Cookies

This website uses cookiesfor statistics and user experience.

This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.

Feel free to read our privacy policy. If you agree to our use, choose Allow all. If you want to change your choice afterwards, you will find that option at the bottom of the page.